Loading
ET
Esperion Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 May 2023.
Esperion Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Esperion Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Ann Arbor, United States. The group dates from 2008. 12 insiders have disclosed 32 filings since 18 October 2025.
Only sales appear on the open market, 11 sales in all totalling €290k, filed by 3 insiders. No amount is published for 3 filings, which the totals therefore leave out. One trade stands out by size: a sale of €151k from Koenig Sheldon L., disclosed on 18 December 2025.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 32 filings, this issuer sits above that mark. Over the whole record (from 2016), the tally stands at 11 purchases and 68 sales. The 10-K for the year ended 31 December 2025 shows 403.1 m USD of revenue and -22.7 m USD of net income.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
152
Thresholds
n/a
Buy Volume
€8M
11 ops. · all time
Sell Volume
€778,841
68 ops. · all time
Who traded when
BuySaleBenjamin Halladay11 sales
Benjamin Looker8 sales
Sheldon L. Koenig7 sales
Warren Eric6 sales
Since the insiders bought
- +58.8%Entry US$1.36 · Close at T+365 US$2.16
- +58.8%Entry US$1.36 · Close at T+365 US$2.16
- +58.8%Entry US$1.36 · Close at T+365 US$2.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Esperion Therapeutics, Inc. Hold (neutral), based on 3 analysts. Average price target: US$3.20.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,889 of 24,158 companies
35.4
score / 100
Value28
Quality43
FCF yld-1.6%
Earn yld-2.8%
EV/EBITDA16.8x
ROE·
Gross mgn68%
Net mgn-5.6%
Debt/EBITDA3.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.18
Analyst consensus
3 analystsHold
US$3.16Target US$3.20(+1%)US$3.28
Income statement
RevenueUS$403.1M
Gross profitUS$273.9M68% margin
EBITDAUS$63.9M16% margin
Net income-US$22.7M-1.8% margin
Valuation
PER (forward)12.3x
Beta1.06
Balance sheet & cash
Market capUS$819.5M
Total debtUS$252.2M
Free Cash Flow-US$13.1M
Profitability & ownership
ROA12.0%
% insiders0.9%
% institutions71.5%
Last declaration on 13 July 2026
Declarations152 total
177,523 sharesCommon StockSEC:0001628280-26-048012:0
2,121,094 sharesCommon StockSEC:0001628280-26-047999:0
705,410 sharesCommon StockSEC:0001628280-26-048000:0
667,524 sharesCommon StockSEC:0001628280-26-048001:0
424,536 sharesCommon StockSEC:0001628280-26-048003:0
79,873 sharesCommon StockSEC:0001628280-26-048006:0
141,023 sharesCommon StockSEC:0001628280-26-048007:0
164,472 sharesCommon StockSEC:0001628280-26-048010:0
85,153 sharesCommon StockSEC:0001628280-26-048014:0
10,773 sharesCommon StockSEC:0001628280-26-044264:0
11,824 sharesCommon StockSEC:0001628280-26-044269:0
53,588 sharesCommon StockSEC:0001628280-26-044266:0
11,824 shares@ US$3.15470.0045% mcap23.4% of flowCommonSEC144:0001959173-26-004744
10,773 shares@ US$3.15470.0041% mcap28.4% of flowCommonSEC144:0001959173-26-004747
53,588 shares@ US$3.15480.020% mcap21.5% of flowCommonSEC144:0001959173-26-004750
79,873 shares0Common StockSEC:0001628280-26-039520:0
79,873 shares0Common StockSEC:0001628280-26-039523:0
79,873 shares0Common StockSEC:0001628280-26-039525:0
79,873 shares0Common StockSEC:0001628280-26-039526:0
79,873 shares0Common StockSEC:0001628280-26-039529:0
5,708 shares@ US$2.7039.7% of flowCommon StockSEC:0001628280-26-019413:0
25,578 shares@ US$2.7198.9% of flowCommon StockSEC:0001628280-26-019411:0
6,424 shares@ US$2.70514.5% of flowCommon StockSEC:0001628280-26-019409:0
300,840 shares0Common StockSEC:0001628280-26-018194:0
723,760 shares0Common StockSEC:0001628280-26-018192:0
25 of 152 declarations
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker ESPR, in the United States (United States). The company is focused on cardiovascular risk reduction, with a commercial and development strategy centered on oral bempedoic acid therapies for patients who are statin intolerant or insufficiently controlled on standard lipid-lowering treatment. From an equity research perspective, Esperion sits in the healthcare/pharma bucket as a specialty cardiometabolic platform with a focused commercial footprint and meaningful pipeline optionality.
Esperion was founded in 2008 and rebuilt around a core scientific asset: bempedoic acid and the related intellectual property rights. Its corporate headquarters are in Ann Arbor, Michigan, giving the company a U.S. life-sciences base in a well-known biotech and academic corridor. Over time, Esperion evolved from a research-driven organization into a commercial-stage company, while still retaining a development mindset aimed at broadening its product set and geographic reach.
Read moreShow less
The company’s marketed portfolio is anchored by NEXLETOL and NEXLIZET, oral therapies used to lower LDL cholesterol in appropriate patients, especially those unable to take statins at effective doses. That places Esperion in a competitive but clinically differentiated niche within the lipid-management market. Its competitive set includes large pharmaceutical franchises in statins, PCSK9 inhibitors and other LDL-lowering therapies, but Esperion’s differentiation lies in oral administration, a statin-intolerance proposition, and an increasingly established evidence base. Inclusion in clinical guidelines and payer access progress are important commercial supports.
Geographically, the United States remains the main revenue engine, although Esperion also operates through collaborators and regulatory filings in international markets. In 2025, management highlighted strong momentum in U.S. prescription growth and product sales, including the milestone of surpassing one million prescriptions for its bempedoic-acid products. The company also discussed new marketing initiatives around statin intolerance and continued work on triple-combination oral products, as well as potential expansion into rare hepatic and renal disease opportunities. A major recent corporate development came in May 2026, when Esperion announced a definitive agreement to be acquired by ARCHIMED in a transaction valued at up to approximately $1.1 billion in total equity value, subject to commercial milestones. For investors tracking ESPR on the NASDAQ, that acquisition announcement is a key near-term strategic catalyst.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
